Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Given the early-stage nature of the collaboration, Aveo will receive $15 million upfront for preclinical antibodies targeting the RON receptor.